The aim of this work was to investigate the FUT2 gene, the secretor status and the expression of CD44 protein in epithelial cells obtain from saliva and urine samples from patients with urogenital tumours. We studied 104 subjects. Half of them had urogenital tumours, while the other half was the healthy control group. We determined the secretor status in saliva with the haemagglutination inhibition technique. We analyzed the FUT2 polymorphism by allele specific oligonucleotide–polymerase chain reaction (ASO-PCR) with specific primers for the G428 allele and the wild type allele of FUT2 gene. We found higher intensity of urogenital disease in the non-secretor group (OR = 3.44). In contrast with the healthy population, 51.6% of the patients with potential malignant urogenital lesions and cancerous lesions were non-secretors. We also investigate by confocal microscopy, the expression of CD44 protein in epithelial cells obtained from urine samples from these patients. The results obtained also showed fluorescence corresponding to the presence of CD44 protein in samples from patients diagnosed with cancer. Our study suggests that the lack of wild type FUT2 gene and a nonsecretor status appear to be an associated risk marker for the development of urogenital tumors. Several mechanisms, based on the properties of CD44 as the major hyaluronan CD44 in cell carcinomas receptor, have been proposed to explain the role of elevated CD44 expression during tumour development and progression. CD44 might be a good candidate as a predictor of prognosis in this group of cancers.
References
[1]
Bryne, M., Boysen, M., Alfsen, C.G., et al. (1998) The Invasive Front of Carcinomas. The Most Important Area for Tumour Prognosis? Anticancer Research, 18, 4757-4764.
[2]
Greenlee, R., Hill-Harmon, M., Murray, T. and Thun, M. (2001) Cancer Statistics. CA: A Cancer Journal for Clinicians, 51, 15-36. https://doi.org/10.3322/canjclin.51.1.15
[3]
Shah, R. and Zhou, M. (2009) Interpretation of Prostate Needle Biopsies. Benign Mimics of Prostate Cancer and Unusal Cancer Morphologies Which Mimic Benign Conditions. USCAP Annual Meeting. http://www.uscap.org/site~/98th/shorth13-5.htm
[4]
Arista-Nasr, J., Martínez-Benítez, B., Fernández-Amador, J.A., Bornstein-Quevedo, L. and Albores-Saavedra, J. (2010) Pseudohyperplastic Carcinoma with Xanthomatous Changes: A Neoplasm Mimicking Glandular Hyperplasia of the Prostate. Actas Urológicas Españolas, 34, 333-339. https://doi.org/10.1016/j.acuro.2009.09.011
[5]
Mazerolles, C. and Chevreau, C. (2007) Tumeur Malignes Rares de la Prostate. Bulletin du Cancer, 94, F44-F49.
[6]
Cartron, J. and Rouger, P. (2001) Bases molèculaires des antigènes des groupes sanguins. De l’immunogenètique à la bioilogic cellulaire, 3rd Edition.
[7]
Yamamoto, F. (2004) Review: ABO Blood Group System. ABH Oligosaccharide Antigens, Anti-A y Anti-B, A and B Glycosyl Transferases, and ABO Genes. Immunohematology, 20, 3-17.
[8]
Henry, L., Oriol, R. and Samuelsson, B. (1995) Lewis Histo-Blood Group System and Associated Secretory Phenotypes. Vox Sanguinis, 69, 166-182. https://doi.org/10.1111/j.1423-0410.1995.tb02591.x
[9]
Nishihara, S., Hiraga, T., Ikehara, Y., Kudo, T., Iwasaki, H., Morozumi, K., et al. (1996) Molecular Mechanisms of the Alternative Names of Secretor (Se) and Lewis (Le) Enzyme Are FUT2 or Fuc-T II, and FUT3 or Fuc-T III, Respectively. 976 Polymorphisms of TwoFucosyltransferase Genes Expression of Lewis b Antigen Andother Type I Lewis Antigens in Human Colorectal Cancer. Glycobiology, 9, 607-617.
[10]
Nishihara, S., Narimatsu, H., Iwasaki, H., Yazawa, S., Akamatsu, S., Ando, T., et al. (1994) Molecular Genetic Analysis of the Human Lewis Histo-Blood Group System. The Journal of Biological Chemistry, 269, 29271-29278.
[11]
Henry, S., Orio, R. and Samuelsson, B. (1995) Lewis Histo-Blood Groupsystem and Associated Secretory Phenotypes. Vox Sanguinis, 69, 166-182. https://doi.org/10.1111/j.1423-0410.1995.tb02591.x
[12]
Hakomori, S. (1999) Antigen Structure and Genetic Basis of Histo-Blood Groups A, B and O: Their Changes Associated with Human Cancer. Biochimica et Biophysica Acta, 1473, 247-266. https://doi.org/10.1016/S0304-4165(99)00183-X
[13]
Campi, C., Escovich, L., Moreno, A., Racca, L., Racca, A., Cotorruelo, C., et al. (2012) Expression of the Gene Encoding Secretor Type Galactoside 2α Fucosyltransferase (FUT2) and ABH Antigens in Patients with Oral Lesions. Medicina Oral Patologia Oral y Cirugia Bucal, 17, e63-e68. https://doi.org/10.4317/medoral.17239
[14]
Marhaba, R. and Zöller, M. (2004) CD44 in Cancer Progression: Adhesion, Migration and Growth Regulation. Journal of Molecular Histology, 35, 211-231. https://doi.org/10.1023/B:HIJO.0000032354.94213.69
[15]
Hudson, D., Speight, P. and Watt, F. (1996) Altered Expression of CD44 Isoforms in Squamous-Cell Carcinomas and Cell Lines Derived from Them. International Journal of Cancer, 66, 457-463. https://doi.org/10.1002/(SICI)1097-0215(19960516)66:4<457::AID-IJC8>3.0.CO;2-V
[16]
Assimakopoulos, D., Kolettas, E., Patrikakos, G. and Evangelou, A. (2002) Therole of CD44 in the Development and Prognosis of Head Andneck Squamous Cell Carcinomas. Histology and Histopathology, 17, 1269-1281.
[17]
Liu, J. and Jiang, G. (2006) CD44 and Hematologic Malignancies. Cellular & Molecular Immunology, 3, 359-365.
[18]
Brecher, M., Butch, S., Calhoun, A., Fiebig, E., et al. (2012) Manual Técnico Asociación Americana de bancos de sangre. 17th Edition.
[19]
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1982) Molecular Cloning: A Laboratory Manual. 2nd Edition, Cold Spring Harbor Laboratory Press, New York.
[20]
Jemal, A., Bray, F., Center, M.M., Ferla, J. and Ward, E. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107
[21]
Dentali, F., Sironi, A.P., Ageno, W., Turato, S., Bonfanti, C., Frattini, F., Crestani, S. and Franchini, M. (2012) Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature. Seminars in Thrombosis and Hemostasis, 38, 535-548. https://doi.org/10.1055/s-0032-1315758
[22]
Kelly, R., Rouquier, S., Giorgi, D., Lennon, G. and Lowe, I. (1995) Sequence and Expression of a Candidate for the Human Secretor Blood Group α(1,2)Fucosyltransferase Gene (FUT2). Homozygosity for an Enzyme-Inactivating Nonsense Mutation Commonly Correlates with the Non-Secretor Phenotype. Journal of Biological Chemistry, 270, 4640-4649. https://doi.org/10.1074/jbc.270.9.4640
[23]
Otavia, L., Caballero, L., de Souza, S., Bretani, R., Simpson, A. (2001) Alternative Spliced Transcripts as Cancer Markers. Disease Markers, 17, 67-75. https://doi.org/10.1155/2001/184856
[24]
Secretor Status (2016) Fut2 Gene and ABH Antigens in Urogenital Tumors Ensinck MA1, Lebensohn N2, García Borrás S3, Racca L4, Cotorruelo C5, Biondi C. IJOER: Engineering Journal, 2, 43-48.